A Phase 1/2a trial of Proxinium in combination with a checkpoint inhibitor for the treatment of late-stage squamous cell carcinoma of the head and neck
Phase of Trial: Phase I/II
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Oportuzumab monatox (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 24 Mar 2017 According to an Eleven Biotherapeutics media release, company anticipates initiating this trial in the second half of 2017.
- 14 Nov 2016 According to an Eleven Biotherapeutics media release, this trial is anticipated to initiate in the first half of 2017.
- 05 Oct 2016 New trial record